Lower-Risk Myelodysplastic Syndromes (LR-MDS): Highlights from EHA 2024  - Episode 16

Final Thoughts on EHA 2024 Data for Lower-Risk MDS

, , , ,

Key opinion leaders summarize their main insights and key takeaways from the EHA 2024 conference regarding advances in lower-risk myelodysplastic syndrome treatment.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Navigating Myelodysplastic Syndromes: Updates to WHO & ICC Guidelines, IPSS-M, and Risk Stratification
    EP. 2: Dr Oliva on Addressing Challenges in Treating Lower-Risk MDS 
    EP. 3: Frontline Therapy for Lower-Risk MDS: Global Perspectives and Treatment Selection Strategies
    EP. 4: Review of the COMMANDS Trial
    EP. 5: Perceptions of the EHA 2024 Full Analysis of the COMMANDs Trial
    EP. 6: Clinical Implications of COMMANDS Trial in Clinical Practice
    EP. 7: Treatment Decision-Making Based on the COMMANDS Trials
    EP. 8: Exploring Biomarker Analysis, Real-World Data, and Quality of Life in LR-MDS: Insights from EHA 2024
    EP. 9: Dr.'s Cluzeau and Komrokji on Utilization Patterns of luspatercept in LR-MDS EHA 2024 Data
    EP. 10: Safety Profile of Available Frontline Treatments LR-MDS
    EP. 11: 1L treatment of lower-risk MDS beyond luspatercept
    EP. 12: Sequencing Second-Line Treatments for LR-MDS
    EP. 13: Perspectives of IMerge Study
    EP. 14: Real-World Evidence and Emerging Therapies in Lower-Risk MDS: Insights from EHA 2024
    EP. 15: EHA 2024 Future Directions in Lower-Risk MDS Treatment: Emerging Data, Approvals, and Guideline Updates
    Now Viewing
    EP. 16: Final Thoughts on EHA 2024 Data for Lower-Risk MDS
    x